日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study

在 Apa-RP 研究中，接受阿帕鲁胺治疗的高危局限性前列腺癌患者皮疹管理指南的影响

期刊:Prostate Cancer and Prostatic Diseases
影响因子:5.8
doi:10.1038/s41391-024-00858-4
Shore, Neal; Hafron, Jason; Saltzstein, Daniel; Bhaumik, Amitabha; Aggarwal, Pankaj; Phillips, Jennifer; McGowan, Tracy
肿瘤
前列腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery

膀胱癌手术前每周服用厄洛替尼的II期临床化学预防试验

期刊:Cancer Prevention Research
影响因子:2.6
doi:10.1158/1940-6207.CAPR-24-0194
Downs, Tracy M; Bailey, Howard H; Lozar, Taja; Schmitz, Natalie S; Green, Heather; Scarlett, Cameron O; Havighurst, Thomas C; Twaroski, Kyleigh; DeShong, Katina; Wollmer, Barbara; Bivalacqua, Trinity J; Saltzstein, Daniel R; Shore, Neal; Kim, KyungMann; Huang, Wei; Ricke, William A; Barroilhet, Lisa; House, Margaret; Parnes, Howard L; Messing, Edward
肿瘤
肿瘤免疫
膀胱癌
发表日期：2025
文献求助 收藏

Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer

放射疗法联合瑞卢戈利治疗局限性或晚期前列腺癌的疗效和安全性

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2023.7279
Spratt, Daniel E; George, Daniel J; Shore, Neal D; Cookson, Michael S; Saltzstein, Daniel R; Tutrone, Ronald; Bossi, Alberto; Brown, Bruce A; Lu, Sophia; Fallick, Mark; Hanson, Sarah; Tombal, Bertrand F
肿瘤
前列腺癌
肿瘤免疫
发表日期：2024
文献求助 收藏

Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP)

阿帕鲁胺治疗根治性前列腺切除术后高危局限性前列腺癌（Apa-RP）

期刊:Journal of Urology
影响因子:6.8
doi:10.1097/JU.0000000000004163
Shore, Neal; Hafron, Jason; Saltzstein, Daniel; Brown, Gordon; Belkoff, Laurence; Aggarwal, Pankaj; Phillips, Jennifer; Bhaumik, Amitabha; McGowan, Tracy
肿瘤
前列腺癌
肿瘤免疫
发表日期：2024
文献求助 收藏

North American study and meta-analysis evaluating performance of Bladder EpiCheck(®), a FDA cleared test, in non-muscle invasive bladder cancer recurrence

北美研究和荟萃分析评估了经FDA批准的膀胱EpiCheck®检测在非肌层浸润性膀胱癌复发中的表现

期刊:Bladder Cancer
影响因子:1.2
doi:10.1177/23523735241304348
Fleshner, Neil; Grossman, Herbert Barton; Berglund, Ryan; Hafron, Jason; Inman, Brant; Karsh, Lawrence; Moses, Kelvin; Saltzstein, Daniel; Shah, Anup; Wright, Jonathan; Witjes, Johannes Alfred; Lotan, Yair
肿瘤
肿瘤免疫
膀胱癌
发表日期：2024
文献求助 收藏

Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)

（18）F-rhPSMA-7.3 正电子发射断层扫描在疑似前列腺癌复发男性中的诊断性能和安全性：一项 3 期前瞻性多中心研究（SPOTLIGHT）的结果

期刊:Journal of Urology
影响因子:6.8
doi:10.1097/JU.0000000000003493
Jani, Ashesh B; Ravizzini, Gregory C; Gartrell, Benjamin A; Siegel, Barry A; Twardowski, Przemyslaw; Saltzstein, Daniel; Fleming, Mark T; Chau, Albert; Davis, Phillip; Chapin, Brian F; Schuster, David M
肿瘤
前列腺癌
肿瘤免疫
发表日期：2023
文献求助 收藏

Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases

阿帕鲁胺和瑞卢戈利联合用于转移风险高的局限性前列腺癌患者

期刊:Targeted Oncology
影响因子:4
doi:10.1007/s11523-022-00932-8
Brown, Gordon; Belkoff, Laurence; Hafron, Jason M; Saltzstein, Daniel R; Potdar, Rushikesh; Bhaumik, Amitabha; Phillips, Jennifer; McGowan, Tracy; Shore, Neal D
肿瘤
前列腺癌
肿瘤免疫
发表日期：2023
文献求助 收藏

Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer

伴随心血管治疗对瑞卢戈利与亮丙瑞林疗效和安全性的影响：HERO研究晚期前列腺癌亚组分析

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-023-02634-7
Shore, Neal D; Mehlhaff, Bryan A; Cookson, Michael S; Saltzstein, Daniel R; Tutrone, Ronald; Brown, Bruce; Lu, Sophia; Fallick, Mark; Hanson, Sarah; Saad, Fred
肿瘤
前列腺癌
肿瘤免疫
发表日期：2023
文献求助 收藏

A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent

一项针对接受雄激素受体靶向药物治疗后病情进展的转移性去势抵抗性前列腺癌患者的Ib/II期研究，评估新型口服细胞骨架破坏剂Sabizabulin的疗效。

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-22-0162
Markowski, Mark C; Tutrone, Ronald; Pieczonka, Christopher; Barnette, K Gary; Getzenberg, Robert H; Rodriguez, Domingo; Steiner, Mitchell S; Saltzstein, Daniel R; Eisenberger, Mario A; Antonarakis, Emmanuel S
肿瘤
肿瘤免疫
信号转导
细胞生物学
前列腺癌
免疫/内分泌
发表日期：2022
文献求助 收藏

Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial

使用含丝裂霉素的反向热凝胶UGN-102（Optima II）对低级别中危非肌层浸润性膀胱癌进行初始化疗消融治疗：一项2b期、开放标签、单臂试验

期刊:Journal of Urology
影响因子:6.8
doi:10.1097/JU.0000000000002186
Chevli, K Kent; Shore, Neal D; Trainer, Andrew; Smith, Angela B; Saltzstein, Daniel; Ehrlich, Yaron; Raman, Jay D; Friedman, Boris; D'Anna, Richard; Morris, David; Hu, Brian; Tyson, Mark; Sankin, Alexander; Kates, Max; Linehan, Jennifer; Scherr, Douglas; Kester, Steven; Verni, Michael; Chamie, Karim; Karsh, Lawrence; Cinman, Arnold; Meads, Andrew; Lahiri, Soumi; Malinowski, Madlen; Gabai, Nimrod; Raju, Sunil; Schoenberg, Mark; Seltzer, Elyse; Huang, William C
肿瘤
肿瘤免疫
膀胱癌
发表日期：2022
文献求助 收藏